SCHEMBL8367136

SCHEMBL8367136

CC1CCC(OC(=O)c2ccccc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
CHRNA7 P36544 3/20 0.58
HTR3E A5X5Y0 1/20 0.58
HTR3B O95264 1/20 0.58
HTR3A P46098 1/20 0.58
HTR3D Q70Z44 1/20 0.58
HTR3C Q8WXA8 1/20 0.58
APOBEC3A P31941 1/20 0.56
APOBEC3G Q9HC16 1/20 0.56
GAA P10253 1/20 0.55
SCN1A P35498 2/20 0.55
SCN2A Q99250 2/20 0.55
SCN3A Q9NY46 2/20 0.55
CARM1 Q86X55 1/20 0.54
PRMT6 Q96LA8 1/20 0.54
LMNA P02545 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
EPHX2 P34913 1/20 0.49
MAPT P10636 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15947407 0.94 MEN1 (0.57) MEN1KMT2ACHRNA7HTR3EHTR3B
SCHEMBL9002108 0.91 SCN1A (0.56) MEN1KMT2ACHRNA7HTR3EHTR3B
SCHEMBL4453290 0.91 MEN1 (0.69) MEN1KMT2ACHRNA7HTR3EHTR3B
SCHEMBL1786140 0.91 MEN1 (0.69) MEN1KMT2ACHRNA7HTR3EHTR3B
Biphenyl SCHEMBL9450695 0.85 SCN1A (0.67) MEN1KMT2ACHRNA7HTR3EHTR3B
SCHEMBL12591313 0.84 SCN1A (0.67) MEN1KMT2ACHRNA7HTR3EHTR3B
SCHEMBL13038152 0.84 SCN1A (0.67) MEN1KMT2AGAASCN1ASCN2A
SCHEMBL19196152 0.84 SCN1A (0.50) MEN1KMT2ASCN1ASCN2ASCN3A
SCHEMBL3233565 0.84 MEN1 (0.61) MEN1KMT2ACHRNA7HTR3EHTR3B
SCHEMBL1896141 0.84 MEN1 (0.61) MEN1KMT2ACHRNA7HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265346-A1 LIQUID CRYSTAL COMPOSITION, OPTICALLY ANISOTROPIC LAYER, LAMINATE, AND IMAGE DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2023-08-24 US disclosed
CN-102378753-B Plasminogen activator-1 inhibitor RENASCIENCE Co.,Ltd. (JP) 2016-03-02 CN disclosed
CN-102378753-A Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO LTD 2012-03-14 CN disclosed
US-7598252-B2 Compounds specific to adenosine A, receptors and uses thereof OSI PHARMACEUTICALS, INC. (US) 2009-10-06 US disclosed
US-20090082369-A1 Pyrrolo[2,3d]pyrimidine compositions and their use OSI PHARMACEUTICALS, INC. 2009-03-26 US disclosed
EP-2011499-A2 Pyrrolo[2,3d]Pyrimidine compositions and their use OSI Pharmaceuticals, Inc. (US) 2009-01-07 EP disclosed
US-7429574-B2 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use OSI PHARMACEUTICALS, INC. (US) 2008-09-30 US disclosed
US-7160890-B2 Compounds specific to adenosine A3 receptor and uses thereof OSI PHARMACEUTICALS, INC. (US) 2007-01-09 US disclosed
US-6680324-B2 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2004-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082369-A1 Pyrrolo[2,3d]pyrimidine compositions and their use ADORA3, ADORA2A, ADORA1 MEN1 3205/4885KMT2A 1854/4885CHRNA7 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.